Published in Vascul Pharmacol on December 20, 2004
1,25(OH)2 vitamin d inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation (2009) 2.36
Variants in the CD36 gene associate with the metabolic syndrome and high-density lipoprotein cholesterol. Hum Mol Genet (2008) 1.98
Molecular basis of human CD36 gene mutations. Mol Med (2007) 1.23
Opposite regulation of CD36 ubiquitination by fatty acids and insulin: effects on fatty acid uptake. J Biol Chem (2008) 1.22
Oxidized glycerophosphocholines as biologically active mediators for ultraviolet radiation-mediated effects. Prostaglandins Other Lipid Mediat (2008) 1.06
Alternative promoter usage of the membrane glycoprotein CD36. BMC Mol Biol (2006) 1.05
The human paraoxonase gene cluster as a target in the treatment of atherosclerosis. Antioxid Redox Signal (2011) 0.95
Resveratrol attenuates oxidized LDL-evoked Lox-1 signaling and consequently protects against apoptotic insults to cerebrovascular endothelial cells. J Cereb Blood Flow Metab (2010) 0.95
Sphingomyelin synthase 2 activity and liver steatosis: an effect of ceramide-mediated peroxisome proliferator-activated receptor γ2 suppression. Arterioscler Thromb Vasc Biol (2013) 0.92
Amphiphilic nanoparticles repress macrophage atherogenesis: novel core/shell designs for scavenger receptor targeting and down-regulation. Mol Pharm (2014) 0.88
Highly upregulated expression of CD36 and MSR1 in circulating monocytes of patients with acute coronary syndromes. Protein J (2012) 0.85
Hexarelin Signaling to PPARgamma in Metabolic Diseases. PPAR Res (2008) 0.82
Expression of both N- and C-terminal GFP tagged huCD36 and their discrepancy in OxLDL and pRBC binding on CHO cells. Lipids Health Dis (2007) 0.81
CD36 signaling inhibits the translation of heat shock protein 70 induced by oxidized low density lipoprotein through activation of peroxisome proliferators-activated receptor gamma. Exp Mol Med (2008) 0.79
Conjugated linoleic acid modulation of risk factors associated with atherosclerosis. Nutr Metab (Lond) (2008) 0.78
Metabolic effects of telmisartan in spontaneously hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol (2006) 0.77
Peroxisome Proliferator-Activator Receptor γ: A Link between Macrophage CD36 and Inflammation in Malaria Infection. PPAR Res (2012) 0.77
Lipoprotein binding preference of CD36 is altered by filipin treatment. Lipids Health Dis (2008) 0.77
Anti-atherosclerotic and anti-inflammatory actions of sesame oil. J Med Food (2015) 0.77
Endoplasmic Reticulum Stress Links Oxidative Stress to Impaired Pancreatic Beta-Cell Function Caused by Human Oxidized LDL. PLoS One (2016) 0.76
CD36 is a co-receptor for hepatitis C virus E1 protein attachment. Sci Rep (2016) 0.76
Microparticles engineered to highly express peroxisome proliferator-activated receptor-γ decreased inflammatory mediator production and increased adhesion of recipient monocytes. PLoS One (2014) 0.76
Macrophagic CD146 promotes foam cell formation and retention during atherosclerosis. Cell Res (2017) 0.75
A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J Biol Chem (2002) 3.17
Inflammation in atherosclerosis and implications for therapy. Circulation (2004) 1.71
Inducible nitric oxide synthase gene deletion exaggerates MAPK-mediated cyclooxygenase-2 induction by inflammatory stimuli. Am J Physiol Heart Circ Physiol (2010) 1.46
Inflammation at the molecular interface of atherogenesis: an anthropological journey. Am J Pathol (2008) 1.15
Functional interplay between the macrophage scavenger receptor class B type I and pitavastatin (NK-104). Circulation (2004) 1.03
Inhibition of ERK1/2 and activation of liver X receptor synergistically induce macrophage ABCA1 expression and cholesterol efflux. J Biol Chem (2009) 0.98
Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone. Am J Pathol (2009) 0.97
Regulation of peroxisome proliferator-activated receptor-gamma-mediated gene expression. A new mechanism of action for high density lipoprotein. J Biol Chem (2002) 0.95
Protein 3-nitrotyrosine in complex biological samples: quantification by high-pressure liquid chromatography/electrochemical detection and emergence of proteomic approaches for unbiased identification of modification sites. Methods Enzymol (2008) 0.95
Pitavastatin downregulates expression of the macrophage type B scavenger receptor, CD36. Circulation (2004) 0.95
Heme catalyzes tyrosine 385 nitration and inactivation of prostaglandin H2 synthase-1 by peroxynitrite. J Lipid Res (2006) 0.95
Profound biopterin oxidation and protein tyrosine nitration in tissues of ApoE-null mice on an atherogenic diet: contribution of inducible nitric oxide synthase. Am J Physiol Heart Circ Physiol (2007) 0.94
Adipogenic differentiating agents regulate expression of fatty acid binding protein and CD36 in the J744 macrophage cell line. J Lipid Res (2003) 0.92
Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells. J Cell Biochem (2003) 0.90
Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression. J Biol Chem (2012) 0.87
Genetic deletion of low density lipoprotein receptor impairs sterol-induced mouse macrophage ABCA1 expression. A new SREBP1-dependent mechanism. J Biol Chem (2007) 0.87
Involvement of the mitogen-activated protein kinase cascade in peroxynitrite-mediated arachidonic acid release in vascular smooth muscle cells. Am J Physiol Cell Physiol (2004) 0.87
Inducible nitric oxide synthase mediates prostaglandin h2 synthase nitration and suppresses eicosanoid production. Am J Pathol (2006) 0.86
Oxidative alterations of cyclooxygenase during atherogenesis. Prostaglandins Other Lipid Mediat (2006) 0.84
Activation of liver X receptor induces macrophage interleukin-5 expression. J Biol Chem (2012) 0.84
Tyrosine nitration in prostaglandin H(2) synthase. J Lipid Res (2002) 0.83
Characterization of a cellular denitrase activity that reverses nitration of cyclooxygenase. Am J Physiol Heart Circ Physiol (2013) 0.81
Silent Partner in Blood Vessel Homeostasis? Pervasive Role of Nitric Oxide in Vascular Disease. Curr Hypertens Rev (2009) 0.80
Maintaining equilibrium by selective targeting of cyclooxygenase pathways: promising offensives against vascular injury. Hypertension (2007) 0.80
Physical evidence for substrate binding in preventing cyclooxygenase inactivation under nitrative stress. J Am Chem Soc (2010) 0.80
Tamoxifen inhibits macrophage FABP4 expression through the combined effects of the GR and PPARγ pathways. Biochem J (2013) 0.79
Inducible nitric oxide synthase provides protection against injury-induced thrombosis in female mice. Am J Physiol Heart Circ Physiol (2011) 0.78
Statins synergize dexamethasone-induced adipocyte fatty acid binding protein expression in macrophages. Atherosclerosis (2012) 0.77
Pitavastatin suppresses mitogen activated protein kinase-mediated Erg-1 induction in human vascular smooth muscle cells. Eur J Pharmacol (2009) 0.76
Reprint of "oxidative alterations of cyclooxygenase during atherogenesis" [Prostag. Oth. Lipid. M. 80 (2006) 1-14]. Prostaglandins Other Lipid Mediat (2007) 0.75